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Minerals, vitamin D, and parathyroid hormone in continuous ambula-
tory peritoneal dialysis. The effects of continuous ambulatory peritoneal
dialysis on parathyroid hormone (PTH) and mineral metabolism were
evaluated in ten patients. Utilizing a PTH radioimmunoassay, which
measures both intact hormone and carboxyl-terminal PTH fragments, it
was found that the mean clearance of immunoreactive parathyroid
hormone was 1.5 0.73 mI/mm (5EM) yielding a daily net removal of
13.6 3.2% of estimated total extracellular parathyroid hormone. Gel
electrophoresis of the dialysate revealed the presence of both intact
parathyroid hormone and fragments in a similar pattern to that of
peripheral plasma. Normal levels of 25-(OH) vitamin D and vitamin D
binding protein were observed prior to the initiation of continuous
ambulatory peritoneal dialysis and following 6 months of treatment.
Timed dialysate collections (N = 93) demonstrated a daily calcium
influx of only 9.9 9.7 mg. The daily removal of phosphorus was 308.4
15.5 mg. Despite elevated serum magnesium levels in all patients, the
net daily removal was inadequate (31.2 15.5 mg). It was concluded
that: (1) Unlike chronic hemodialysis, continuous ambulatory peritone-
al dialysis removes significant amounts of parathyroid hormone. (2)
Normal 25-(OH) vitamin D and vitamin D binding protein levels are
maintained with continuous ambulatory peritoneal dialysis despite large
protein losses. (3) Substantial amounts of phosphorus are removed with
continuous ambulatory peritoneal dialysis but not to an extent that
precludes use of phosphorus binders. (4) Dialysate containing lower
magnesium and possibly higher calcium concentrations should be made
available to improve mineral homeostasis.
Minerals, vitamine D, et l'hormone parathyroidienne en dialyse pen-
tonéale continue ambulatoire. Les effets de la dialyse péritondale
continue ambulatoire sur l'hormone parathyroIdienne (PTH) et le
métabolisme mineral étaient évalué en 10 malades. En utilisant un
dosage radio-immunologique de Ia PTH mesurant a Ia fois l'hormone
intacte et les fragments carboxyl-teriminaux de Ia PTH, il a été trouvé
que Ia clearance moyenne de l'hormone parathyroIdienne immunordac-
tive était de 1,5 0,73 mI/mn (sEM), ce qui donne une épuration
journalière nette de 13,6 3,2% de l'hormone parathyroidienne extra-
cellulaire totale estimée. Une electrophorese sur gel de Ia dialysat a
montré Ia presence de l'hormone parathyroIdienne intacte et de frag-
ments avec un aspect similaire a celui du plasma peripherique. Des
valeurs normales de 25-hydroxyvitamine D et de protéine de liaison de
Ia vitamine D ont été observées avant le debut de Ia dialyse peritoneale
continue ambulatoire, et au bout de 6 mois de traitement. Des recueils
répétés du dialysat (N = 93) ont démontré que l'infiux calciquejournalier n'était que de 9,9 9,7 mg. L'épuration journalière de
phosphore était de 308,4 15,5 mg. Malgré des concentrations seriques
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élevées de magnesium chez tous les malades, l'epuration journalire
nette de magnesium était inappropnée (31,2 15,5 mg). 11 était conclu:
(1) A Ia difference de l'hemodialyse chronique, Ia dialyse pCritonéale
continue ambulatoire retire des quantites significatives d'hormone
parathyroidienne; (2) les concentrations de 25 (OH)-vitamine D et de
protéine de liaison de Ia vitamine D se maintiennent a des valeurs
normales en dialyse péritoneale continue ambulatoire, malgré d'impor-
tantes pertes protéiques; (3) des quantités substantielles de phosphate
sont retirees par la dialyse peritoneale continue ambulatoire, sans
toutefois que cette quantité permette l'abandon des bloqueurs de
l'absorption de phosphate; (4) un dialysat contenant moms de magne-
sium et probablement plus de calcium devrait être disponible afin
d'améliorer l'homéostasis minérale.
As the lives of patients with renal failure are prolonged with
chronic dialysis therapy, increasing attention is being directed
toward an understanding of the mechanisms which underlie the
various metabolic abnormalities seen in uremia. Disorders of
mineral and bone metabolism play a prominent role in the
development of not only renal osteodystrophy [11, but may also
affect muscular [21, cardiovascular [3], and neurological func-
tions [4] in renal failure.
Renal osteodystrophy refers to all skeletal disorders that
occur in patients with renal failure: osteitis fibrosa cystica,
osteomalacia, osteosclerosis, osteoporosis, and growth retarda-
tion. In the adult North American population osteitis fibrosa
cystica and, to a lesser extent, osteomalacia, comprise the
majority of lesions noted on bone biopsy specimens in patients
with renal failure.
Osteitis fibrosa cystica results from high levels of parathyroid
hormone causing bone resorption. Increased numbers of osteo
clasts, increased amounts of woven osteoid, and excessive
numbers of }{owslip's lucunae are present on bone biopsy
specimens [5]. There are several reasons for elevated levels of
parathyroid hormone in renal failure. Hypocalcemia directly
stimulates parathyroid hormone secretion. Elevated phospho
rus levels, impaired intestinal absorption of calcium, and resist
ance of bone to the calcemic action of parathyroid hormon
may all work in concert to lower calcium levels in severe renaJ
failure [1]. Conservative measures to suppress parathyroid
hormone secretion, such as aluminum hydroxide binders arni
calcium and/or vitamin D supplements, are often efficacious in
controlling the development or progression of osteitis fibrosa
cystica.
With the institution of chronic hemodialysis, further changes
in bone and mineral metabolism occur. Approximately 700 to
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Fig. 1. Daily calcium mass transfer in patients on CAPD and effects of
solution composition. A small positive net transfer of calcium (9.8 mg)
occurred with each 1.5% solution exchange. A negative mass transfer of
21 mg ensued with the 4.25% solution exchanges. This resulted in a
modest positive daily mass transfer of calcium (9.9 mg).
1100 mg of calcium enter the patient during a 10-hr Kiil dialysis
when the dialysate calcium level exceeds the diffusable concen-
tration in plasma by 1.5 to 2.0 mg/dl [61. Depending on the
magnitude of the hyperphosphatemia, the efficiency of the
dialyzer, and the duration of dialysis, as much as 1000 to 1200
mg of phosphorus may be removed during a single hemodialysis
treatment. Parathyroid hormone or its fragments are not re-
moved from the circulation by hemodialysis. Although 1,25
dihydroxy vitamin D levels remain persistently low, 25-hydroxy
vitamin D concentrations are usually normal in patients on
chronic hemodialysis [71.
The pathogenesis of osteomalacia (or defective mineraliza-
tion of bone) is unclear. The finding that defective mineraliza-
tion is more common in uremic patients in the United Kingdom
than in the United States and that the patients in the former
group have lower serum levels of 25-hydroxy vitamin D sug-
gests that deficiencies in this metabolite may contribute to the
development of osteomalacia [81. Goldstein et al reported that
25-hydroxy vitamin D levels are depressed in patients with
nephrotic syndrome and normal renal function [9]. The authors
hypothesized that 25-hydroxy vitamin D and its carrier protein
vitamin D binding protein, were lost in the urine resulting in low
25-hydroxy vitamin D levels. Mild osteomalacia was detected
by bone biopsy analysis in those patients [101.
Continuous ambulatory peritoneal dialysis is a relatively new
modality in the treatment of patients with renal failure. Com-
pared to chronic hemodialysis, continuous ambulatory perito-
neal dialysis is associated with far greater losses of middle (500
to 5000 daltons) and large molecular weight protein fractions.
These differences potentially may lead to profound changes in
mineral, vitamin D, and parathyroid hormone metabolism. The
purpose of this study was therefore to: (1) evaluate calcium,
phosphorus, and magnesium fluxes in patients treated with
continuous ambulatory peritoneal dialysis, (2) determine the
effect of continuous ambulatory peritoneal dialysis on parathy-
roid hormone metabolism, and (3) to ascertain if patients on
continuous ambulatory peritoneal dialysis were able to maintain
normal 25-hydroxy vitamin D levels despite large daily losses of
protein.
Methods
Ten patients maintained on continuous ambulatory peritoneal
dialysis (CAPD) for a mean duration of 11 months were studied.
There were five females and five males with a mean age of 51
years. Of the seven patients who began CAPD without previous
dialysis therapy, four had been nephrotic and had creatinine
clearances less than 4 mI/mm. Within 2 to 3 months on CAPD,
all subsequently became oliguric. Three patients were treated
with hemodialysis for more than 1 year prior to CAPD and were
anuric. All patients were maintained on oral aluminum hydrox-
ide gels in order to maintain the serum phosphorus levels
between 4 and 5.5 mgldl and oral calcium supplements to
maintain plasma ionized calcium values between 4.5 and 5.0
mg/dl. None took corticosteroid or anticonvulsant medications.
One patient was maintained on 25-hydroxy vitamin D
[25(OH)D] while on chronic hemodialysis (CHD) for more than
5 years prior to CAPD. It was continued during treatment with
CAPD.
The patients exchanged three 1.5% and one 4.25% dextrose
dialysate solutions (Dianeal, Baxter-Travenol Laboratories,
Deerfield, Illinois) per day. The dwell times were 4 to 4.5 and 7
to 8 hr, respectively. Serum levels of immunoreactive parathy-
roid hormone (i-PTH), ionized calcium, phosphorus, and mag-
nesium were determined monthly. Serum levels of 25(OH)D
were assayed at the institution of CAPD and after 6 months.
Timed dialysate samples were collected at home during the 24
hr prior to the patients' clinic appointments and were frozen at
—20° C until analyzed for total calcium, phosphorus, magne-
sium, and i-PTH. In addition, timed clearances and mass
transfer studies were performed in the Clinical Research Center
(CRC) at the Washington University School of Medicine in all
patients every 6 months. The values obtained in the CRC were
identical to those obtained from outpatients and were pooled.
Signed informed consent approved by the Washington Univer-
sity School of Medicine Human Studies Committee was ob-
tained on all patients.
Inulin clearances were performed every 6 months in the
CRC. Fifty mg/kg of inulin was infused over 5 mm, 2 hr prior to
a 4-hr 1.5% dextrose exchange. Blood samples were obtained at
the beginning, middle, and end of the 1.5% dextrose exchange
and analyzed for inulin, ionized calcium, phosphorus, magne-
sium, and i-PTH. The mean of the three values for inulin was
used to calculate the serum inulin concentrations during the
clearance study.
Determinations. Total calcium and magnesium levels were
determined by atomic absorption spectometry (Perkin-Elmer,
Model 503). Ionized calcium was measured with the Orion flow-
through electrode. Phosphorus was determined by routine
laboratory methods adapted for the Technicon Auto Analyzer
(Technicon Instruments Corporation, Tarrytown, New York).
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_Fig. 3. Daily phosphorus mass transfer in patients on CAPD and
effects of solution composition. Approximately 66 mg were removed
with each 1.5% solution exchange, and Ill mg were removed following
a 4.25% solution exchange. This resulted in a phosphorus removal of
308 mg124 hr.
Inulin was measured by the method of Brown and Nolph [11].
Radioimmunoassay of PTH was performed as previously
described in detail [12]. Determinations of the multiple forms of
immunoreactive PTH were performed by polyacrylamide gel
electrophoresis [13]. Immunoreactive PTH was extracted from
plasma and dialysate by absorption to microfined silica (Quso
0-32), eluted with 30% acetone, 1% acetic acid, and lyophi-
lized. The dried residue was extracted with 8 M urea and 0.1 M
acetic acid prior to gel electrophoresis. Gel slices were eluted in
0.2 M barbital containing 10% hypoparathyroid serum at pH 7.4,
and analyzed by radioimmunoassay as previously described
[13].
Vitamin D binding protein (DBP) and 25(OH)D were assayed
according to methods previously described [14, 15].
Calculations. The mass transfer of substances was calculated
by the net amount removed per exchange from the amount
instilled:
Mass transfer = Dialysate concentration instilled x Dialysate
volume instilled — Dialysate concentration
postexchange x Dialysate volume postexchange.
A positive net transfer therefore represents the amount
accruing within the patient and a negative net mass transfer the
amount removed. The concentration of total calcium and mag-
nesium consistently were found to be 7.0 mgldl and 1.8 mg/dl,
respectively, in multiple batches of both 1.5 and 4.25% dextrose
Dianeal bags. The value used for the volume of instilled
dialysate was 2050 ml.
Timed clearances were calculated using the standard
formula:
Dialysate concentration Dialysate volume (ml)C (mI/mm) =
.
x
Plasma concentration Time (mm)
Statistics. Statistical analyses were performed using the
Student's paired and unpaired t test and by the analysis of
covariance. All values are reported as mean SEM.
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Fig. 2. Daily calcium mass transfer in relation to serum ionized calcium
levels. The normal range is 4.4 to 5.0 mg/dl. Abbreviation used is Ca,
calcium.
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Fig. 4. Phosphorus mass transfer with each 1.5%solution in relation to
serum phosphorus levels. Abbreviation used is P, phosphorus.
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Fig. 5. Daily magnesium mass transfer in patients on CAPD and effects
of solution composition. Exchanges with 1.5% and 4.25% solutions
resulted in the removal of 5 mg and 19 mg of magnesium, respectively.
This resulted in a removal of 31 mg/24 hr.
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Results
Calcium, phosphorus, and magnesium mass transfer. The
mean net daily balance of calcium was only 9.9 mg (Fig. 1). A
mean of 9.8 mg of calcium entered the patient with every 1.5%
solution. However, a net calcium loss of 21 mg occurred with
each 4.25% solution.
The mean ionized calcium level in the patients treated with
CAPD was 4.9 0.1 mg/dl based on 31 determinations (normal
range 4.4 to 5.0 mg/dl). The daily mass transfer of calcium was
then evaluated in relation to the corresponding serum ionized
calcium levels (Fig. 2). There was a net calcium removal of 77
23 mg during periods of hypercalcemia, yet little uptake of
calcium from the dialysate during periods of hypocalcemia (48
13 mg).
The mean alimentary fasting phosphorus level in the patients
was 5.2 0.4 mgldl. The amount of phosphorus removed daily
was 308 22 mg (Fig. 3). The negative mass transfer was 66 3
mg with each 1.5% and 111 4 mg with each 4.25% dextrose
exchange. As one might expect, the amount of phosphorus
removed correlated with the serum phosphorus levels (Fig. 4).
Timed fasting 4-hr clearances of phosphorus using 1.5% dex-
trose exchanges was 4.71 0.27 ml/min (N = 11).
The magnesium levels were elevated in all patients averaging
3.41 mgldl. The total daily removal of magnesium was 31 15
mg (Fig. 5). Only 5 2 mg were removed with the 1.5% and 19
5 mg with the 4.25% dextrose exchanges.
25-OH vitamin D and vitamin binding protein (DBP) studies.
The concentrations of 25(OH)D in patients treated by CAPD
(excluding the one patient treated with 25(OH)D for 6 months)
were compared to age-, race-, and sex-matched patients main-
tamed on chronic hemodialysis between 6 and 12 months. The
concentrations of 25(OH)D in those patients treated with CAPD
were 21 3 ng/ml (normal range, 15 to 30 ng/ml) (Fig. 6). These
levels were not different from those of chronic hemodialysis
patients, 28 6 nglml. In addition, serial levels of 25(OH)D did
not change in five patients before and after 6 months of CAPD
treatment.
The normal range of DBP (molecular weight, 57,000 daltons),
the major serum protein carrier of 25(OH)D, is 400 to 650 gIml.
The patients treated by CAPD for 6 months had levels of DBP
within the normal range (610 21 g/ml) (Fig. 7). These
concentrations were higher than those of matched chronic
hemodialysis patients, 503 26 p.g/ml (P < 0.02). These results
were somewhat surprising since 6.2 2.2 mg of DBP were
removed with each 1.5% dextrose exchange.
Studies of immunoreactive parathyroid hormone (iPTH).
Timed clearances of inulin and iPTH were performed in eight
patients during a 4-hr exchange using 1.5% dextrose solutions.
The mean iPTH clearance was 1.56 0.73 mllmin and correlat-
ed (r = 0.828) with the clearance of inulin, a molecule of similar
molecular weight as the carboxy terminal fragments of PTH
(Fig. 8). The amount of iPTH lost daily into the dialysate was
measured 24 times in eight patients. Assuming the volume of
distribution of iPTH to be 20% of total body weight, 13.6% of
iPTH was removed per day with CAPD. However, there were
no overall differences in the serum levels of iPTH measured in
those patients prior to and after 6 months of CAPD. In those
four patients in whom the iPTH levels did not change after 6
months of CAPD, the clearance was 1.1 0.35 mI/mm, and in
those four in whom it fell the clearance was 2.0 0,61 ml/min.
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Fig. 6. Serum levels of 25-hydroxy Vitamin D in patients on CAPD 11l
and hemodialysis L. The dotted lines encompass the normal range.
866 Delmez et a!
I
6 months Chronic
on CAPD hemodialysisN8 patientsN 15
Fig. 7. Serum levels of vitamin D binding protein in patients on CAPD
M and hemodialysis Lii. The dotted lines encompass the normal range.
Because circulating iPTH in renal failure is comprised of both
intact hormone and fragments [161, gel electrophoresis of the
plasma and dialysate was performed. The electrophoretic pat-
tern of each was similar (Fig. 9). The majority of iPTH detected
was comprised of carboxy terminal fragments with small quan-
tities of intact hormone being present.
Discussion
The finding of minimal net positive transfer of calcium during
CAPD is different from the data of Parker and Nolph [17]. If one
recalculates their data, a positive calcium balance of 300 mg per
day would accrue using three 1.5% and one 4.25% dextrose
exchanges daily. The reasons for this discrepancy are unclear.
The patients described by Parker and Noiph were not on oral
calcium supplements, and no values were given for their levels
of ionized calcium. Gokal et al [18] have reported that serum
ionized calcium levels were low in patients on CAPD who did
not receive oral calcium supplements. If the patients studied by
Parker and Nolph had lower ionized calcium levels than those
reported here, the positive mass transfer would, of course, be
greater.
The optimal protein intake required for patients on CAPD is
unclear. Short-term studies by Blumenkrantz et al [19} suggest
that positive nitrogen balance may be achieved on a 1.0 g
proteinlkg/day diet containing 42 1 kcal/kg/day. This diet
requires an obligate daily ingestion of between 800 and 1000 mg
of phosphorus of which approximately 400 to 500 mg are
absorbed. Since an average of only 300 mg of phosphorus are
removed daily by CAPD, the use of oral aluminum hydroxide
binders is usually necessary to maintain near normal phospho-
rus levels.
Approximately 100 mg of magnesium are absorbed per day
from a diet containing 300 mg [201. With a daily removal of only
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Fig. 8. Simultaneous clearances of immunoreactive PTH and inulin
with 1.5% solutions during a 4-hr dwell. The clearances of the two
substances correlated closely.
31 mg of magnesium via the peritoneal dialysate, it is likely that
patients maintained on CAPD are in positive magnesium bal-
ance. This balance was reflected in the elevated concentrations
of serum magnesium in all patients. The pathophysiological
significance of this is unclear. An increase in serum magnesium
concentrations is associated with an increased content of mag-
nesium in bone, which in turn may alter crystal formation [21].
The normal levels of 25(OH)D in patients on CAPD is
noteworthy. Goldstein et al [9] report low levels of 25(OH)D in
patients with nephrotic syndrome and normal renal function
and suggest that this metabolite may be depleted by the losses
of its carrier protein, DBP, into the urine. The patients de-
scribed herein had rates of daily protein losses into the dialysate
(7.4 0.7 g) which are comparable to the urinary losses seen in
patients with nephrotic syndrome. This strongly suggests that
protein losses do not necessarily directly alter vitamin D
metabolism. It is possible that, in nephrotic syndrome, alter-
ations at any one of the numerous hydroxylation steps of
vitamin D metabolism may be altered or that the kinetics of
DBP turnover may be different in the nephrotic syndrome and
CAPD.
It is not surprising that iPTH levels did not fall in all patients
on CAPD. The concentration of iPTH depends on the rate of
secretion versus endogenous peripheral metabolism. Although
iPTH is lost in significant amounts in the dialysate, it is
unknown how important and relative this is in quantitative
terms to the endogenous metabolic clearance of iPTH. None-
theless, if iPTH secretion can be controlled, it is likely that
CAPD, unlike CHD, can serve as an additional avenue for iPTH
removal and may lower iPTH levels. The degree to which the
removal of iPTH or lowering of iPTH levels during CAPD
reflects changes in the biological activity of this hormone is
unknown.
We have demonstrated that CAPD removes substantial quan-
tities of immunoreactive parathyroid hormone. The electropho-
retic pattern in the dialysate is similar to that detected in the
serum. Despite large losses of protein in the dialysate, the
25(OH)D and DBP levels are maintained. However, the influx
of calcium and effiux of magnesium may be insufficient for
optimal mineral metabolism in CAPD. These studies suggest
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